Constipation is a condition in which stool frequency drops to three times per week and stool passage becomes difficult. Constipation is a frequent functional gastrointestinal condition that can have a negative impact on a patient's life. The occurrence of persistent constipation symptoms with no well-defined underlying cause is referred to as chronic idiopathic constipation. Infrequent bowel motions, firm stools, straining during defecation, a sense of incomplete evacuation, stomach pain, and bloating are all signs of chronic idiopathic constipation. Laboratory studies, endoscopy, radiographic examinations, magnetic resonance imaging, and physiological testing are used to identify chronic idiopathic constipation. Currently, there are only a few authorized treatment options for chronic idiopathic constipation, which is likely to be a key stumbling block to the chronic idiopathic constipation treatment market growth. This, on the other hand, permits a market participant to develop a unique therapy to get a foothold in the rapidly increasing chronic idiopathic constipation treatment market.
Increasing clinical studies and pharmaceutical company approval of drug candidates to meet unmet medical requirements of chronic idiopathic constipation therapy is a significant driver driving market expansion during the predicted period. For example, Shire plc obtained a new drug application from the US Food and Drug Administration in March 2018 for its drug candidate SHP555 (prucalopride) for the treatment of persistent idiopathic constipation in adults. SHP555 (prucalopride) was also approved by the European Commission in 2015 for the symptomatic treatment of persistent constipation in individuals who had failed to respond to laxative therapy. Renexxion is also undertaking a phase 2 clinical study for Naronapride (ATI-7505), which is being developed for the treatment of a variety of gastrointestinal diseases, including chronic idiopathic constipation. Ironwood and Allergan's Linzess (linaclotide) were authorized by the FDA in 2017 for the treatment of chronic idiopathic constipation. However, 50 percent of chronic constipation patients are unsatisfied with their present therapy, owing to ineffectiveness, highlighting the ongoing medical need for more effective and safer therapeutic treatments.